Harshpreet Kaur, Neha Sharma, Joy Das, Mandeep Kaur, Navneet Khurana
{"title":"Bridging Gaps in Postpartum Depression Research: Pathways to Personalized Medicine in Women's Mental Health.","authors":"Harshpreet Kaur, Neha Sharma, Joy Das, Mandeep Kaur, Navneet Khurana","doi":"10.2174/0118715273426978260515114857","DOIUrl":null,"url":null,"abstract":"<p><p>Postpartum depression (PPD) is a prevalent and serious mental health disorder that affects nearly 15% of women after childbirth. It disrupts maternal well-being, infant development, and family relationships, and often remains underdiagnosed due to its complex biological, psychological, and social determinants. Conventional treatment strategies largely follow generalized, symptom-based approaches that fail to address the wide individual variation in hormonal sensitivity, genetic background, and psychosocial context among affected women. This review emphasizes the importance of adopting a personalized medicine framework for the management of PPD. Relevant literature was systematically reviewed from major databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar, focusing on studies published between January 2018 and September 2025. The search covered biological mechanisms, psychosocial influences, and innovative therapeutic approaches integrating pharmacogenomics, hormonal profiling, and culturally sensitive psychotherapies. The analysis highlights that personalized strategies, combining genetic testing for antidepressant response, individualized hormonal modulation, and context-based psychological interventions, offer improved therapeutic precision compared to conventional models. Emerging technologies such as digital health tools and telemedicine further enhance individualized care delivery. Clinically, the integration of personalized medicine transforms PPD management from a uniform, symptom-oriented approach to a patient-centered model that aligns biological and psychosocial dimensions. This paradigm shift has the potential to enhance treatment response, accelerate recovery, and strengthen longterm maternal and child outcomes.</p>","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715273426978260515114857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Postpartum depression (PPD) is a prevalent and serious mental health disorder that affects nearly 15% of women after childbirth. It disrupts maternal well-being, infant development, and family relationships, and often remains underdiagnosed due to its complex biological, psychological, and social determinants. Conventional treatment strategies largely follow generalized, symptom-based approaches that fail to address the wide individual variation in hormonal sensitivity, genetic background, and psychosocial context among affected women. This review emphasizes the importance of adopting a personalized medicine framework for the management of PPD. Relevant literature was systematically reviewed from major databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar, focusing on studies published between January 2018 and September 2025. The search covered biological mechanisms, psychosocial influences, and innovative therapeutic approaches integrating pharmacogenomics, hormonal profiling, and culturally sensitive psychotherapies. The analysis highlights that personalized strategies, combining genetic testing for antidepressant response, individualized hormonal modulation, and context-based psychological interventions, offer improved therapeutic precision compared to conventional models. Emerging technologies such as digital health tools and telemedicine further enhance individualized care delivery. Clinically, the integration of personalized medicine transforms PPD management from a uniform, symptom-oriented approach to a patient-centered model that aligns biological and psychosocial dimensions. This paradigm shift has the potential to enhance treatment response, accelerate recovery, and strengthen longterm maternal and child outcomes.
产后抑郁症(PPD)是一种普遍而严重的精神健康障碍,影响了近15%的分娩后妇女。它会扰乱孕产妇福祉、婴儿发育和家庭关系,由于其复杂的生物、心理和社会决定因素,它往往仍未得到充分诊断。传统治疗策略在很大程度上遵循广义的、基于症状的方法,未能解决受影响妇女在激素敏感性、遗传背景和社会心理环境方面的广泛个体差异。这篇综述强调了采用个性化医疗框架来管理PPD的重要性。系统梳理了PubMed、Scopus、Web of Science、ScienceDirect、b谷歌Scholar等主要数据库的相关文献,重点关注2018年1月至2025年9月之间发表的研究。这项研究涵盖了生物学机制、社会心理影响以及整合药物基因组学、激素谱和文化敏感心理疗法的创新治疗方法。分析强调,与传统模型相比,个性化策略,结合抗抑郁反应的基因检测,个性化激素调节和基于情境的心理干预,提供了更高的治疗精度。数字卫生工具和远程医疗等新兴技术进一步加强了个性化医疗服务。在临床上,个性化医疗的整合将PPD管理从统一的、以症状为导向的方法转变为以患者为中心的模式,使生物和社会心理维度保持一致。这种模式转变有可能加强治疗反应,加速康复,并加强孕产妇和儿童的长期结局。